Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The companys proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc Key Recent Developments

Mar 25,2021: Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
Feb 11,2021: Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
Feb 11,2021: Alkermes reports financial results for the fourth quarter and year ended Dec. 31, 2020 and provides financial expectations for 2021
Feb 04,2021: Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
Jan 06,2021: Alkermes announces updates to executive leadership team

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Section 1 - About the Company
Alkermes Plc - Key Facts
Alkermes Plc - Key Employees
Alkermes Plc - Key Employee Biographies
Alkermes Plc - Major Products and Services
Alkermes Plc - History
Alkermes Plc - Company Statement
Alkermes Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Alkermes Plc - Business Description
Product Category: Aristada/Aristada Initio
Overview
Performance
Product Category: Vivitrol
Overview
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alkermes Plc - Corporate Strategy
Alkermes Plc - SWOT Analysis
SWOT Analysis - Overview
Alkermes Plc - Strengths
Alkermes Plc - Weaknesses
Alkermes Plc - Opportunities
Alkermes Plc - Threats
Alkermes Plc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alkermes Plc, Recent Deals Summary
Section 5 Companys Recent Developments
Mar 25, 2021: Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
Feb 11, 2021: Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
Feb 11, 2021: Alkermes reports financial results for the fourth quarter and year ended Dec. 31, 2020 and provides financial expectations for 2021
Feb 04, 2021: Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
Jan 06, 2021: Alkermes announces updates to executive leadership team
Dec 11, 2020: Alkermes, Syneos Health, Neuro-Behavioral Clinical Research, Depression Bipolar and Support Alliance, and Matthew Shapiro Win the STARR Coalition STARR of Excellence 2020 Awards
Dec 10, 2020: Alkermes announces strategic value enhancement plan and continued board refreshment
Oct 29, 2020: Alkermes reports third quarter 2020 financial results and raises 2020 financial expectations
Jul 29, 2020: Alkermes reports second quarter 2020 financial results and issues 2020 financial expectations
Jun 29, 2020: Alkermes announces launch of 3rd annual Alkermes pathways research awards program
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Alkermes Plc, Key Facts
Alkermes Plc, Key Employees
Alkermes Plc, Key Employee Biographies
Alkermes Plc, Major Products and Services
Alkermes Plc, History
Alkermes Plc, Other Locations
Alkermes Plc, Subsidiaries
Alkermes Plc, Key Competitors
Alkermes Plc, Ratios based on current share price
Alkermes Plc, Annual Ratios
Alkermes Plc, Annual Ratios (Cont...1)
Alkermes Plc, Interim Ratios
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alkermes Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Alkermes Plc, Performance Chart (2016 - 2020)
Alkermes Plc, Ratio Charts
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The companys proprietary products

USD 250 View Report

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review

Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The companys proprietary products

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available